ESCMID Global 2025: Real-world effectiveness of PCV20 against IPD and ACP among older adults in the US
25 Jun 2025
byMs. Amanda Miles, Vaccines Real World Evidence Scientist of Pfizer Vaccines, New York, New York, US
At the 2025 Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025), Ms Amanda Miles, Vaccines Real World Evidence Scientist of Pfizer Vaccines, New York, New York, US, presented the first real-world (RW) data showing the effectiveness of the 20-valent pneumococcal conjugate vaccine (PCV20) in preventing invasive pneumococcal disease (IPD) and all-cause pneumonia (ACP) among US adults aged ≥65 years.